News
September 27, 2023
TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting
September 5, 2023
TScan Therapeutics to Participate in Upcoming Investor Conferences
August 29, 2023
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME
August 10, 2023
TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
June 29, 2023
TScan Therapeutics Announces Transition of Chief Financial Officer
June 6, 2023
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors
June 1, 2023
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting
June 1, 2023
TScan Therapeutics Announces Closing of Public Offering
June 1, 2023
TScan Therapeutics to Participate in the Jefferies Healthcare Conference
May 26, 2023